Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Pipeline
  • Pharma Pipeline Stalls for First Time in Decades: Citeline
  • Pipeline

Pharma Pipeline Stalls for First Time in Decades: Citeline

BioSpace

Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.

PipelineRead full story

pharminent April 6, 2026 (Last updated: April 6, 2026)

BioSpace

Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.

PipelineRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
Next: Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal

Related Stories

  • Pipeline

Sanofi drops two more programmes in R&D clear-out

pharminent July 30, 2026
  • Pipeline

Lundbeck preps for key bexicaserin data around year-end

pharminent July 20, 2026
  • Pipeline

AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist

pharminent July 10, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.